Literature DB >> 24259977

Prognostic factors in non-malignant and non-cirrhotic patients with portal cavernoma: an 8-year retrospective single-center study.

Xing-Shun Qi1, Ming Bai, Chuang-Ye He, Zhan-Xin Yin, Wen-Gang Guo, Jing Niu, Fei-Fei Wu, Guo-Hong Han.   

Abstract

AIM: To evaluate the outcome of non-malignant and non-cirrhotic patients with portal cavernoma and to determine the predictors for survival.
METHODS: Between July 2002 and June 2010, we retrospectively enrolled all consecutive patients admitted to our department with a diagnosis of portal cavernoma without abdominal malignancy or liver cirrhosis. The primary endpoint of this observational study was death and cause of death. Independent predictors of survival were identified using the Cox regression model.
RESULTS: A total of 64 patients were enrolled in the study. During a mean follow-up period of 18 ± 2.41 mo, 7 patients died. Causes of death were pulmonary embolism (n = 1), acute leukemia (n = 1), massive esophageal variceal hemorrhage (n = 1), progressive liver failure (n = 2), severe systemic infection secondary to multiple liver abscesses (n = 1) and accident (n = 1). The cumulative 6-, 12- and 36-mo survival rates were 94.9%, 86% and 86%, respectively. Multivariate Cox regression analysis demonstrated that the presence of ascites (HR = 10.729, 95%CI: 1.209-95.183, P = 0.033) and elevated white blood cell count (HR = 1.072, 95%CI: 1.014-1.133, P = 0.015) were independent prognostic factors of non-malignant and non-cirrhotic patients with portal cavernoma. The cumulative 6-, 12- and 36-mo survival rates were significantly different between patients with and without ascites (90%, 61.5% and 61.5% vs 97.3%, 97.3% and 97.3%, respectively, P = 0.0008).
CONCLUSION: The presence of ascites and elevated white blood cell count were significantly associated with poor prognosis in non-malignant and non-cirrhotic patients with portal cavernoma.

Entities:  

Keywords:  Ascites; Extrahepatic portal vein obstruction; Portal cavernoma; Prognostic factors; Survival

Mesh:

Year:  2013        PMID: 24259977      PMCID: PMC3831228          DOI: 10.3748/wjg.v19.i42.7447

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

Review 1.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

2.  Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.

Authors:  Xingshun Qi; Cheng Zhang; Guohong Han; Wei Zhang; Chuangye He; Zhanxin Yin; Zhiwei Liu; Wei Bai; Ruijun Li; Ming Bai; Zhiping Yang; Kaichun Wu; Daiming Fan
Journal:  J Gastroenterol Hepatol       Date:  2012-06       Impact factor: 4.029

3.  Anticoagulation for portal vein thrombosis in cirrhosis.

Authors:  Xingshun Qi; Guohong Han; Kaichun Wu; Daiming Fan
Journal:  Am J Med       Date:  2010-09       Impact factor: 4.965

4.  The epidemiology and clinical features of portal vein thrombosis: a multicentre study.

Authors:  R Rajani; E Björnsson; A Bergquist; A Danielsson; A Gustavsson; O Grip; T Melin; P Sangfelt; S Wallerstedt; S Almer
Journal:  Aliment Pharmacol Ther       Date:  2010-09-15       Impact factor: 8.171

5.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

6.  Prevalence of paroxysmal nocturnal hemoglobinuria in Chinese patients with Budd-Chiari syndrome or portal vein thrombosis.

Authors:  Xingshun Qi; Chuangye He; Guohong Han; Zhanxin Yin; Feifei Wu; Qing Zhang; Jing Niu; Kaichun Wu; Daiming Fan
Journal:  J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 4.029

7.  The aetiology, presentation and natural history of extra-hepatic portal venous obstruction.

Authors:  L J Webb; S Sherlock
Journal:  Q J Med       Date:  1979-10

8.  Formation of hilar collaterals or cavernous transformation after portal vein obstruction by hepatocellular carcinoma. Observations in ten patients.

Authors:  K Ohnishi; K Okuda; T Ohtsuki; T Nakayama; Y Hiyama; S Iwama; N Goto; Y Nakajima; N Musha; T Nakashima
Journal:  Gastroenterology       Date:  1984-11       Impact factor: 22.682

Review 9.  Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment.

Authors:  Francesca R Ponziani; Maria A Zocco; Chiara Campanale; Emanuele Rinninella; Annalisa Tortora; Luca Di Maurizio; Giuseppe Bombardieri; Raimondo De Cristofaro; Anna M De Gaetano; Raffaele Landolfi; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

10.  Transjugular intrahepatic portosystemic shunt in the treatment of portal vein thrombosis: a critical review of literature.

Authors:  Xingshun Qi; Guohong Han
Journal:  Hepatol Int       Date:  2011-12-01       Impact factor: 6.047

View more
  3 in total

1.  An early decision of transjugular intrahepatic portosystemic shunt may be considered for non-malignant and non-cirrhotic portal vein thrombosis with ascites: a concise review of the theoretical possibility and practical difficulty.

Authors:  Xingshun Qi; Xiaozhong Guo
Journal:  Arch Med Sci       Date:  2016-10-24       Impact factor: 3.318

Review 2.  Optimal Treatment for Patients With Cavernous Transformation of the Portal Vein.

Authors:  Bo Wei; Zhiyin Huang; Chengwei Tang
Journal:  Front Med (Lausanne)       Date:  2022-03-24

3.  Outcome of the Pediatric Patients with Portal Cavernoma: The Retrospective Study for 10 Years Focusing on Recurrent Variceal Bleeding.

Authors:  Hongjie Guo; Fabao Hao; Chunbao Guo; Yang Yu
Journal:  Gastroenterol Res Pract       Date:  2016-02-02       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.